BC
CRL icon

Bayforest Capital’s Charles River Laboratories CRL Stock Holding History

Bayforest Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$356K Buy
1,570
+1,360
+648% +$242K 0.33% 38
2026
Q1 		$36.2K Buy
210
+17
+9% +$3.15K 0.04% 642
2025
Q4 		$38.5K Sell
193
-770
-80% -$140K 0.03% 627
2025
Q3 		$151K Buy
963
+546
+131% +$86.7K 0.07% 446
2025
Q2 		$63.3K Buy
+417
New +$55.6K 0.03% 512

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Bayforest Capital's CRL Position: Q2 2026 in Review

Bayforest Capital increased its Charles River Laboratories (CRL) stake by 648% in Q2 2026, buying an estimated $242K and bringing the position to 1,570 shares worth $356K. The position accounts for 0.33% of the portfolio, ranked #38.

Bayforest Capital first reported a position in CRL in Q2 2025 and has held it in 5 quarters since. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Bayforest Capital held 1,570 shares of Charles River Laboratories worth $356K as of Q2 2026.
  • Bayforest Capital bought 1,360 Charles River Laboratories shares in Q2 2026, an estimated $242K.
  • Charles River Laboratories made up 0.33% of Bayforest Capital's portfolio in Q2 2026, its #38 holding.
  • Bayforest Capital first reported a position in Charles River Laboratories in Q2 2025 and has held it in 5 quarters since.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.